Clinical Trial Update: Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of rituximab, bendamustine, and lenalidomide in aggressive B-cell lymphoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED